However, panels involving those markers could be considered for non-invasive screening in high-risk populations such as patients with strong familial history of breast/ovarian cancer and with BRCA1 or BRCA2 (breast cancer gene 1 and 2, respectively) mutations where early and more accurate OC detection would facilitate the determination of the optimal time for preventive surgery. This evidence concerns the gene BRCA1 and ovarian cancer.